Test drug combo for newly diagnosed CLL in Chinese adults
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests acalabrutinib together with obinutuzumab in people with newly diagnosed chronic lymphocytic leukemia (CLL) to see how well the combination works. It may help by improving control of the cancer, but you’ll be closely monitored for side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 18 or older.
- Your CLL must be a specific type: CD20-positive CLL, and it must meet official CLL diagnosis rules.
- Your CLL must be “active” and in need of treatment based on symptoms or lab/organ changes.
- Your general strength is acceptable (ECOG 0–2) and hasn’t worsened over the last 2 weeks.
- Your blood counts and organ tests must be within allowed ranges (including white cells, platelets, liver tests, and kidney function).
- You can swallow the study medicines and are willing to complete all study visits and consent to sharing health info.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies how well acalabrutinib works when combined with either venetoclax or obinutuzumab in people with untreated chronic lymphocytic leukemia (CLL). It aims to improve disease control while checking safety and tolerability.
This Phase 2 trial studies whether acalabrutinib, and optionally adding obinutuzumab, can control early-stage chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It aims to see how well these treatments work and how safe they are in people who have not had prior treatment.
This trial tests whether adding acalabrutinib to obinutuzumab plus venetoclax works better than the standard combo (obinutuzumab plus venetoclax) for people with untreated, high-risk CLL. It’s designed to see if the stronger mix can improve control of the leukemia with an acceptable safety profile.
This Phase 1 study tests a new combination of medicines to treat people whose chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) has not been treated before and needs therapy. It aims to shrink the disease and control it safely in this early testing stage.
This trial tests a combination of three drugs (zanubrutinib, sonrotoclax, and obinutuzumab) for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have not had treatment before. The goal is to see if this combination works well and is safe.
This trial tests two different drug combinations (venetoclax with obinutuzumab or with acalabrutinib) to see how they affect the risk of tumor lysis syndrome in people with untreated CLL or SLL. It may help find the safest and most effective way to start treatment.
Hear when a new Chronic Lymphocytic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.